Modafinil is a benzhydryl-class eugeroic stimulant first developed in France in the late 1970s by neurophysiologist Michel Jouvet and Lafon Laboratories. It is the main metabolite of adrafinil, with U.S. medical approval granted in 1998. It is prescribed for narcolepsy, sleep apnea, and shift work disorder, and is also commonly used off-label as a cognitive enhancer because its stimulant profile is relatively subtle compared with traditional stimulants.
Modafinil molecular structure diagram from the DrugsPRO substance library.
Also known as: Alertec, Provigil, Modiodal, Modalert, Modvigil
Classification
Chemical: Medicine
Psychoactive: Stimulant
Tag: Benzhydryl
Tag: Diphenylmethylsulfinylacetamide
Tag: Eugeroic
Effects
Stimulation
Headache
Diarrhea
Increased Heart Rate
Nausea
Insomnia
Wakefulness
Focus Enhancement
Thought Acceleration
Memory Enhancement
Motivation Enhancement
Anxiety
Dehydration
Photophobia
Appetite Suppression
Light Sensitivity
Increased Music Appreciation
Increased Libido
Routes of Administration
Oral
Dosage
Heavy: 300 mg
Light: 50 – 100 mg
Common: 100 – 200 mg
Strong: 200 – 300 mg
Threshold: 50 mg
Duration
Onset: 1-2 h
Comeup: 0.3-1 h
Peak: 3.5-5 h
Offset: 1-3 h
After Effects: 2-6 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Modafinil - Ghid de substanțe DrugsPRO
Modafinil: Modafinil is a benzhydryl-class eugeroic stimulant first developed in France in the late 1970s by neurophysiologist Michel Jouvet and Lafon Laboratories. It is the main metabolite of adrafinil, with U.S. medical approval granted in 1998. It is prescribed for narcolepsy, sleep apnea, and s